Skip to main content
. 2020 Aug 18;11:1787. doi: 10.3389/fimmu.2020.01787

Figure 3.

Figure 3

The divergence of DNA methylation landscape between CD123 CAR-T cells pretreated with and without DAC. (A) CD123 CAR-T cells from three patients (P1, P2, P3) and three healthy donors (H1, H2, H3) were treated with or without 1 μM DAC for 48 h. Illumina Infnium HD Methylation 850 K arrays were used to determine the DNA methylation status. Differential methylation CpG sites whose case Diffscore < −13 or >13 (p < 0.05) and case Delta_Beta >0.17 or < −0.17 were presented. (B) Percentage of high (β-values >0.8), medium (0.2 < β-values <0.8) and low (β-values <0.2) methylation level was presented with or without DAC pretreatment. (C) CD123 CAR-T cells from patients were treated with a series of doses of DAC for 12, 24, or 48 h. Whole-cell lysates were subjected to western blotting analysis to examine the protein levels of total DNMT1 and DNMT3a. β-actin was used as loading control. The data are representative of three determinations with identical results.